slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,061-6,090
Pages 296
Rows per page 30
Slide type
6,061-6,090 of 8,880
27
The slide uses two line charts to demonstrate the superior durability of CD4 T cells in a serial killing assay.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
36
The left side uses a funnel diagram to represent the manufacturing process steps.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
39
The slide uses a four-column layout to summarize the therapeutic profile of the drug candidate.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
42
The slide outlines a manufacturing process for off-the-shelf cell therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
45
The slide uses a structural diagram to explain the three components of the molecule and a process diagram to show the biological interaction.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
46
Includes a schematic diagram of the bispecific molecule on the left.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
48
The chart uses a broken axis to show early time points and late-stage tumor volume divergence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
49
The slide uses a 3x4 grid of line charts to demonstrate the safety profile of the proprietary TCER format.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
51
Includes ISH images, a prevalence table, and a dot plot comparing peptide density.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
60
The slide uses a visual metaphor of cell-to-cell interaction to illustrate the therapeutic mechanism.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
61
The funnel is represented as a series of concentric circles/segments.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
62
The chart is a dot plot showing quantitative target density (CpC) for two different peptide targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
63
The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
64
The slide uses a comparative framework to explain the safety profile of their technology platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
65
The slide uses a flywheel-style circular diagram to represent the iterative nature of the data platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
12
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations, demonstrating superior performance for HSL.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
13
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
16
Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
50
The slide uses a process-flow style layout to connect the platform's core capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
Includes a comparative size diagram of the drug vs IgG antibody and a Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
Includes multiple citations and diagrams illustrating the mechanism of action and clinical results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
57
The slide uses a side-by-side comparison structure to explain two distinct proprietary platforms.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit